Anette-G. Ziegler
Research Subjects
Anette-G. Ziegler has a total of 106 co-authors. Here are the top co-authors by number of shared publications:
- Ezio Bonifacio
Center for Regenerative Therapies Dresden, Technische Universität Dresden, Dresden, Germany
25 shared publications - Peter Achenbach
Institute of Diabetes Research, Helmholtz Zentrum München, German Research Center for Environmental Health, Munich-Neuherberg, Germany
7 shared publications Christiane Winkler
Institute of Diabetes Research, Helmholtz Zentrum München, and Forschergruppe Diabetes, Klinikum rechts der Isar; Technische Universität München; Neuherberg Germany
5 shared publicationsMichael Hummel
Institut für Diabetesforschung der Forschergruppe Diabetes e.V. am Helmholtz Zentrum München, Munich, Germany
5 shared publicationsM. Hummel
Diabetes Research Institute
4 shared publicationsMaren Pflüger
Institut für Diabetesforschung der Forschergruppe Diabetes e.V. am Helmholtz Zentrum München, Munich, Germany
4 shared publications
Latest Publications
- 29 June 2016
- Published by Georg Thieme Verlag KG in Diabetes aktuell
- Vol. 14 (04) , 186-191
Gestationsdiabetes postpartal – Typ-2-Diabetes-Risikoabschätzung und präventive Therapie
Ein Schwangerschaftsdiabetes erhöht das Risiko, später im Leben an einem Typ-2-Diabetes zu erkranken. Jede zweite Frau mit Gestationsdiabetes mellitus (GDM) entwickelt innerhalb von 10 Jahren nach der Entbindung einen Typ-2-Diabetes, obwohl sich ihr Blutzuckerspiegel nach der Schwangerschaft zunächst wieder normalisiert. Zahlreiche Risikofaktoren, wie z. B. Insulintherapie während der Schwangerschaft und Adipositas in der frühen Schwangerschaft, werden mit der Entwicklung eines Typ-2-Diabetes postpartum in Verbindung gebracht. Wissenschaftler vom Institut für Diabetesforschung, Helmholtz Zentrum München, haben nun einen Risiko-Score entwickelt, der eine gute Abschätzung des Typ-2-Diabetes Risikos postpartum anhand weniger, leicht erfassbarer klinischer Variablen ermöglicht. Eine Risikoabschätzung ist essenziell für die adäquate Planung von Kontrolluntersuchungen beim betreuenden Arzt. Women with gestational diabetes mellitus (GDM) are at increased risk of developing type 2 diabetes postpartum. Every second woman with GDM is developing type 2 diabetes within the next 10 years after delivery, although her elevated blood glucose levels most often resolve directly after pregnancy. Postpartum diabetes risk can be stratified by variables such as insulin treatment during pregnancy and obesity in early pregnancy. Recently, scientists from the Institute of Diabetes Research, Helmholtz Zentrum München, developed a simple tool to detect women's individual diabetes risk after a pregnancy complicated by GDM. Accurate prediction of GDM-related postpartum diabetes is essential for clinicians and general practitioners to plan preventive medical check-ups.
- 29 June 2016
- Published by Georg Thieme Verlag KG in Diabetes aktuell
- Vol. 14 (04) , 186-191
Gestationsdiabetes postpartal – Typ-2-Diabetes-Risikoabschätzung und präventive Therapie
Ein Schwangerschaftsdiabetes erhöht das Risiko, später im Leben an einem Typ-2-Diabetes zu erkranken. Jede zweite Frau mit Gestationsdiabetes mellitus (GDM) entwickelt innerhalb von 10 Jahren nach der Entbindung einen Typ-2-Diabetes, obwohl sich ihr Blutzuckerspiegel nach der Schwangerschaft zunächst wieder normalisiert. Zahlreiche Risikofaktoren, wie z. B. Insulintherapie während der Schwangerschaft und Adipositas in der frühen Schwangerschaft, werden mit der Entwicklung eines Typ-2-Diabetes postpartum in Verbindung gebracht. Wissenschaftler vom Institut für Diabetesforschung, Helmholtz Zentrum München, haben nun einen Risiko-Score entwickelt, der eine gute Abschätzung des Typ-2-Diabetes Risikos postpartum anhand weniger, leicht erfassbarer klinischer Variablen ermöglicht. Eine Risikoabschätzung ist essenziell für die adäquate Planung von Kontrolluntersuchungen beim betreuenden Arzt. Women with gestational diabetes mellitus (GDM) are at increased risk of developing type 2 diabetes postpartum. Every second woman with GDM is developing type 2 diabetes within the next 10 years after delivery, although her elevated blood glucose levels most often resolve directly after pregnancy. Postpartum diabetes risk can be stratified by variables such as insulin treatment during pregnancy and obesity in early pregnancy. Recently, scientists from the Institute of Diabetes Research, Helmholtz Zentrum München, developed a simple tool to detect women's individual diabetes risk after a pregnancy complicated by GDM. Accurate prediction of GDM-related postpartum diabetes is essential for clinicians and general practitioners to plan preventive medical check-ups.
- 21 February 2014
- Published by Hindawi Limited in Pediatric Diabetes
- Vol. 15 (7) , 534-542
Early infant growth is associated with the risk of islet autoimmunity in genetically susceptible children
Background Islet autoimmunity commonly develops early in infancy. We assessed whether specific parameters of early growth (including weight gain) were associated with the development of islet autoimmunity in children of type 1 diabetes patients, taking individual developmental patterns into account. Methods Growth parameters were estimated in n = 1011 children followed from birth in the prospective BABYDIAB and BABYDIET studies using longitudinal models. Cox proportional hazard models, adjusted for study, sex, gestational age, birth weight percentile, and maternal type 1 diabetes status, were calculated to assess hazard ratios (HR) for islet autoimmunity with corresponding 95% confidence intervals (95% CI) by 2 SD increases in growth parameters. In a subset of n = 170 infants, we investigated whether the growth hormones insulin‐like growth factor‐1 (IGF‐1) and insulin‐like growth factor‐binding protein‐3 (IGFBP‐3) were in the causal pathway. Results We found an early age at infant body mass index (BMI) peak to be associated with the development of islet autoimmunity [HR 0.60 (95% CI 0.41–0.87), per 2 SD increase in age]. Islet autoimmunity was also associated with BMI difference between infant BMI peak and childhood BMI rebound [HR 1.52 (95% CI 1.04–2.22)], but not after adjustment for age at infant BMI peak, and not with other parameters such as peak height and weight velocity during infancy. Serum concentrations of IGF‐1 and IGFBP‐3 at birth, 9 months, and 2 yr, respectively, were not significantly different between children with and without later islet autoimmunity. Conclusions Variations in early growth rate have subtle effects on the risk of islet autoimmunity with growth hormones unlikely to be in the causal pathway.
- 21 February 2014
- Published by Hindawi Limited in Pediatric Diabetes
- Vol. 15 (7) , 534-542
Early infant growth is associated with the risk of islet autoimmunity in genetically susceptible children
Background Islet autoimmunity commonly develops early in infancy. We assessed whether specific parameters of early growth (including weight gain) were associated with the development of islet autoimmunity in children of type 1 diabetes patients, taking individual developmental patterns into account. Methods Growth parameters were estimated in n = 1011 children followed from birth in the prospective BABYDIAB and BABYDIET studies using longitudinal models. Cox proportional hazard models, adjusted for study, sex, gestational age, birth weight percentile, and maternal type 1 diabetes status, were calculated to assess hazard ratios (HR) for islet autoimmunity with corresponding 95% confidence intervals (95% CI) by 2 SD increases in growth parameters. In a subset of n = 170 infants, we investigated whether the growth hormones insulin‐like growth factor‐1 (IGF‐1) and insulin‐like growth factor‐binding protein‐3 (IGFBP‐3) were in the causal pathway. Results We found an early age at infant body mass index (BMI) peak to be associated with the development of islet autoimmunity [HR 0.60 (95% CI 0.41–0.87), per 2 SD increase in age]. Islet autoimmunity was also associated with BMI difference between infant BMI peak and childhood BMI rebound [HR 1.52 (95% CI 1.04–2.22)], but not after adjustment for age at infant BMI peak, and not with other parameters such as peak height and weight velocity during infancy. Serum concentrations of IGF‐1 and IGFBP‐3 at birth, 9 months, and 2 yr, respectively, were not significantly different between children with and without later islet autoimmunity. Conclusions Variations in early growth rate have subtle effects on the risk of islet autoimmunity with growth hormones unlikely to be in the causal pathway.
- Open Access
- 17 October 2011
- Published by American Diabetes Association in Diabetes
- Vol. 60 (11) , 2740-2747
Age- and Islet Autoimmunity–Associated Differences in Amino Acid and Lipid Metabolites in Children at Risk for Type 1 Diabetes
OBJECTIVE: Islet autoimmunity precedes type 1 diabetes and often initiates in childhood. Phenotypic variation in islet autoimmunity relative to the age of its development suggests heterogeneous mechanisms of autoimmune activation. To support this notion, we examined whether serum metabolite profiles differ between children with respect to islet autoantibody status and the age of islet autoantibody development. RESEARCH DESIGN AND METHODS: The study analyzed 29 metabolites of amino acid metabolism and 511 lipids assigned to 12 lipid clusters in children, with a type 1 diabetic parent, who first developed autoantibodies at age 2 years or younger (n = 13), at age 8 years or older (n = 22), or remained autoantibody-negative, and were matched for age, date of birth, and HLA genotypes (n = 35). Ultraperformance liquid chromatography and mass spectroscopy were used to measure metabolites and lipids quantitatively in the first autoantibody-positive and matched autoantibody-negative serum samples and in a second sample after 1 year of follow-up. RESULTS: Differences in the metabolite profiles were observed relative to age and islet autoantibody status. Independent of age-related differences, autoantibody-positive children had higher levels of odd-chain triglycerides and polyunsaturated fatty acid–containing phospholipids than autoantibody-negative children and independent of age at first autoantibody appearance (P < 0.0001). Consistent with our hypothesis, children who developed autoantibodies by age 2 years had twofold lower concentration of methionine compared with those who developed autoantibodies in late childhood or remained autoantibody-negative (P < 0.0001). CONCLUSIONS: Distinct metabolic profiles are associated with age and islet autoimmunity. Pathways that use methionine are potentially relevant for developing islet autoantibodies in early infancy.
- 17 October 2011
- Published by American Diabetes Association in Diabetes
- Vol. 60 (11) , 2740-2747
Open AccessAge- and Islet Autoimmunity–Associated Differences in Amino Acid and Lipid Metabolites in Children at Risk for Type 1 Diabetes
OBJECTIVE: Islet autoimmunity precedes type 1 diabetes and often initiates in childhood. Phenotypic variation in islet autoimmunity relative to the age of its development suggests heterogeneous mechanisms of autoimmune activation. To support this notion, we examined whether serum metabolite profiles differ between children with respect to islet autoantibody status and the age of islet autoantibody development. RESEARCH DESIGN AND METHODS: The study analyzed 29 metabolites of amino acid metabolism and 511 lipids assigned to 12 lipid clusters in children, with a type 1 diabetic parent, who first developed autoantibodies at age 2 years or younger (n = 13), at age 8 years or older (n = 22), or remained autoantibody-negative, and were matched for age, date of birth, and HLA genotypes (n = 35). Ultraperformance liquid chromatography and mass spectroscopy were used to measure metabolites and lipids quantitatively in the first autoantibody-positive and matched autoantibody-negative serum samples and in a second sample after 1 year of follow-up. RESULTS: Differences in the metabolite profiles were observed relative to age and islet autoantibody status. Independent of age-related differences, autoantibody-positive children had higher levels of odd-chain triglycerides and polyunsaturated fatty acid–containing phospholipids than autoantibody-negative children and independent of age at first autoantibody appearance (P < 0.0001). Consistent with our hypothesis, children who developed autoantibodies by age 2 years had twofold lower concentration of methionine compared with those who developed autoantibodies in late childhood or remained autoantibody-negative (P < 0.0001). CONCLUSIONS: Distinct metabolic profiles are associated with age and islet autoimmunity. Pathways that use methionine are potentially relevant for developing islet autoantibodies in early infancy.
- Open Access
- 20 September 2011
- Published by Springer Nature in Diabetologia
- Vol. 54 (12) , 2995-3002
Human enterovirus infections in children at increased risk for type 1 diabetes: the Babydiet study
The aim of this study was to examine human enteroviruses (HEVs) and other intestinal viruses derived from children who participated in the Babydiet intervention study and to analyse the findings according to the appearance of islet autoantibodies, dietary intervention, maternal type 1 diabetes and clinical symptoms. In the Babydiet study the influence of first gluten exposure (6 or 12 months) on the development of islet autoimmunity was investigated in 150 children with increased genetic and familial risk for type 1 diabetes. Blood and stool samples were collected at 3 monthly intervals until the age of 3 years and yearly thereafter. Infections and clinical symptoms were recorded daily for the first year. In the present study, 339 stool samples collected from 104 children during the first year of life were analysed for HEVs and a certain proportion of the samples were analysed for other intestinal viruses. HEV was detected in 32 (9.4%) samples from 24 (23.1%) children. Altogether 13 serotypes were identified, with HEV-A species being the most common. Children with gastrointestinal symptoms had norovirus (3/11) and sapovirus (1/11) infections in addition to HEV (1/11). Of the 104 children, 22 developed islet autoantibodies. HEV infections were detected in 18% (4/22) and 24% (20/82) of islet-autoantibody-positive and -negative children, respectively (p = 0.5). The prevalence of HEV was similar in the gluten-exposed groups and in children from mothers with type 1 diabetes or from affected fathers and/or siblings (p = 1.0 and 0.6, respectively). No correlation was found between the presence of HEV in the first year of life and the development of islet autoantibodies. There was no association between HEV infections and dietary intervention, maternal diabetes or clinical symptoms.
- 20 September 2011
- Published by Springer Nature in Diabetologia
- Vol. 54 (12) , 2995-3002
Open AccessHuman enterovirus infections in children at increased risk for type 1 diabetes: the Babydiet study
The aim of this study was to examine human enteroviruses (HEVs) and other intestinal viruses derived from children who participated in the Babydiet intervention study and to analyse the findings according to the appearance of islet autoantibodies, dietary intervention, maternal type 1 diabetes and clinical symptoms. In the Babydiet study the influence of first gluten exposure (6 or 12 months) on the development of islet autoimmunity was investigated in 150 children with increased genetic and familial risk for type 1 diabetes. Blood and stool samples were collected at 3 monthly intervals until the age of 3 years and yearly thereafter. Infections and clinical symptoms were recorded daily for the first year. In the present study, 339 stool samples collected from 104 children during the first year of life were analysed for HEVs and a certain proportion of the samples were analysed for other intestinal viruses. HEV was detected in 32 (9.4%) samples from 24 (23.1%) children. Altogether 13 serotypes were identified, with HEV-A species being the most common. Children with gastrointestinal symptoms had norovirus (3/11) and sapovirus (1/11) infections in addition to HEV (1/11). Of the 104 children, 22 developed islet autoantibodies. HEV infections were detected in 18% (4/22) and 24% (20/82) of islet-autoantibody-positive and -negative children, respectively (p = 0.5). The prevalence of HEV was similar in the gluten-exposed groups and in children from mothers with type 1 diabetes or from affected fathers and/or siblings (p = 1.0 and 0.6, respectively). No correlation was found between the presence of HEV in the first year of life and the development of islet autoantibodies. There was no association between HEV infections and dietary intervention, maternal diabetes or clinical symptoms.
- 1 August 2011
- Published by Elsevier in Journal of Autoimmunity
- Vol. 37 (1) , 3-7
Accelerated progression from islet autoimmunity to diabetes is causing the escalating incidence of type 1 diabetes in young children
- 1 August 2011
- Published by Elsevier in Journal of Autoimmunity
- Vol. 37 (1) , 3-7
Accelerated progression from islet autoimmunity to diabetes is causing the escalating incidence of type 1 diabetes in young children
- Open Access
- 20 May 2011
- Published by American Diabetes Association in Diabetes Care
- Vol. 34 (6) , 1301-1305
Primary Dietary Intervention Study to Reduce the Risk of Islet Autoimmunity in Children at Increased Risk for Type 1 Diabetes
OBJECTIVE To determine whether delaying the introduction of gluten in infants with a genetic risk of islet autoimmunity is feasible, safe, and may reduce the risk of type 1 diabetes–associated islet autoimmunity. RESEARCH DESIGN AND METHODS A total of 150 infants with a first-degree family history of type 1 diabetes and a risk HLA genotype were randomly assigned to a first gluten exposure at age 6 months (control group) or 12 months (late-exposure group) and were followed 3 monthly until the age of 3 years and yearly thereafter for safety (for growth and autoantibodies to transglutaminase C [TGCAs]), islet autoantibodies to insulin, GAD, insulinoma-associated protein 2, and type 1 diabetes. RESULTS Adherence to the dietary-intervention protocol was reported from 70% of families. During the first 3 years, weight and height were similar in children in the control and late-exposure groups, as was the probability of developing TGCAs (14 vs. 4%; P = 0.1). Eleven children in the control group and 13 children in the late-exposure group developed islet autoantibodies (3-year risk: 12 vs. 13%; P = 0.6). Seven children developed diabetes, including four in the late-exposure group. No significant differences were observed when children were analyzed as per protocol on the basis of the reported first gluten exposure of the children. CONCLUSIONS Delaying gluten exposure until the age of 12 months is safe but does not substantially reduce the risk for islet autoimmunity in genetically at-risk children.
- 20 May 2011
- Published by American Diabetes Association in Diabetes Care
- Vol. 34 (6) , 1301-1305
Open AccessPrimary Dietary Intervention Study to Reduce the Risk of Islet Autoimmunity in Children at Increased Risk for Type 1 Diabetes
OBJECTIVE To determine whether delaying the introduction of gluten in infants with a genetic risk of islet autoimmunity is feasible, safe, and may reduce the risk of type 1 diabetes–associated islet autoimmunity. RESEARCH DESIGN AND METHODS A total of 150 infants with a first-degree family history of type 1 diabetes and a risk HLA genotype were randomly assigned to a first gluten exposure at age 6 months (control group) or 12 months (late-exposure group) and were followed 3 monthly until the age of 3 years and yearly thereafter for safety (for growth and autoantibodies to transglutaminase C [TGCAs]), islet autoantibodies to insulin, GAD, insulinoma-associated protein 2, and type 1 diabetes. RESULTS Adherence to the dietary-intervention protocol was reported from 70% of families. During the first 3 years, weight and height were similar in children in the control and late-exposure groups, as was the probability of developing TGCAs (14 vs. 4%; P = 0.1). Eleven children in the control group and 13 children in the late-exposure group developed islet autoantibodies (3-year risk: 12 vs. 13%; P = 0.6). Seven children developed diabetes, including four in the late-exposure group. No significant differences were observed when children were analyzed as per protocol on the basis of the reported first gluten exposure of the children. CONCLUSIONS Delaying gluten exposure until the age of 12 months is safe but does not substantially reduce the risk for islet autoimmunity in genetically at-risk children.
- 29 March 2011
- Published by Wiley in Pediatric Diabetes
- Vol. 13 (5) , 419-424
Prospective evaluation of risk factors for the development of islet autoimmunity and type 1 diabetes during puberty - TEENDIAB: study design
Anette‐Gabriele Ziegler, Franziska Meier‐Stiegen, Christiane Winkler, Ezio Bonifacio, the TEENDIAB Study Group. Prospective evaluation of risk factors for the development of islet autoimmunity and type 1 diabetes during puberty – TEENDIAB: study design. Type 1 diabetes (T1D) has a peak incidence in childhood and adolescence. The TEENDIAB study investigates the period of puberty and adolescence in the natural course of T1D development. Evidence suggests that the immune phenotype of children developing autoimmunity during puberty and adolescence differs from that in childhood. We hypothesize that these differences reflect heterogeneity in the genetic and environmental factors that influence the development of autoimmunity in puberty versus early infancy. TEENDIAB is an observational cohort study that enrols and follows 1500 children aged 8–12 and who have a first degree relative with T1D to test this hypothesis. Data collection and analyses will focus on determining the phenotype of islet autoimmunity, genotypes of T1D‐ and type 2 diabetes‐associated genes, insulin resistance, and β‐cell function, growth, obesity, and physical exercise. The findings of this study will increase the understanding of pathogenetic mechanisms behind the increasing diabetes incidence in youth and the impact of obesity on diabetes development in this age period.
- 29 March 2011
- Published by Wiley in Pediatric Diabetes
- Vol. 13 (5) , 419-424
Prospective evaluation of risk factors for the development of islet autoimmunity and type 1 diabetes during puberty - TEENDIAB: study design
Anette‐Gabriele Ziegler, Franziska Meier‐Stiegen, Christiane Winkler, Ezio Bonifacio, the TEENDIAB Study Group. Prospective evaluation of risk factors for the development of islet autoimmunity and type 1 diabetes during puberty – TEENDIAB: study design. Type 1 diabetes (T1D) has a peak incidence in childhood and adolescence. The TEENDIAB study investigates the period of puberty and adolescence in the natural course of T1D development. Evidence suggests that the immune phenotype of children developing autoimmunity during puberty and adolescence differs from that in childhood. We hypothesize that these differences reflect heterogeneity in the genetic and environmental factors that influence the development of autoimmunity in puberty versus early infancy. TEENDIAB is an observational cohort study that enrols and follows 1500 children aged 8–12 and who have a first degree relative with T1D to test this hypothesis. Data collection and analyses will focus on determining the phenotype of islet autoimmunity, genotypes of T1D‐ and type 2 diabetes‐associated genes, insulin resistance, and β‐cell function, growth, obesity, and physical exercise. The findings of this study will increase the understanding of pathogenetic mechanisms behind the increasing diabetes incidence in youth and the impact of obesity on diabetes development in this age period.
- 3 December 2010
- Published by Springer Nature in Diabetologia
- Vol. 54 (3) , 699-700
Anti-CCL3 autoantibodies are not markers of type 1 diabetes when measured by a commercial ELISA method
- 3 December 2010
- Published by Springer Nature in Diabetologia
- Vol. 54 (3) , 699-700
Anti-CCL3 autoantibodies are not markers of type 1 diabetes when measured by a commercial ELISA method
- Open Access
- 11 May 2010
- Published by American Diabetes Association in Diabetes
- Vol. 59 (8) , 2063-2067
BMI at Age 8 Years Is Influenced by the Type 2 Diabetes Susceptibility Genes HHEX-IDE and CDKAL1
OBJECTIVE To determine whether HHEX-IDE and CDKAL1 genes, which are associated with birth weight and susceptibility to type 2 diabetes, continue to influence growth during childhood. RESEARCH DESIGN AND METHODS BMI, weight, and height at age 8 years expressed as age- and sex-corrected standard deviation scores (SDS) against national reference data and single-nucleotide polymorphism genotyping of HHEX-IDE and CDKAL1 loci were analyzed in 646 prospectively followed children in the German BABYDIAB cohort. All children were singleton full-term births; 386 had mothers with type 1 diabetes, and 260 had fathers with type 1 diabetes and a nondiabetic mother. RESULTS Type 2 diabetes risk alleles at the HHEX-IDE locus were associated with reduced BMI-SDS at age 8 years (0.17 SDS per allele; P = 0.004). After stratification for birth weight, both HHEX-IDE and CDKAL1 risk alleles were associated with reduced BMI-SDS (0.45 SDS, P = 0.0002; 0.52 SDS, P = 0.0001) and weight-SDS (0.22 SDS, P = 0.04; 0.56 SDS, P = 0.0002) in children born large for gestational age (>90th percentile) but not children born small or appropriate for gestational age. Within children born large for gestational age, BMI and weight decreased with each additional type 2 diabetes risk allele (∼ −2 kg per allele; >8 kg overall). Findings were consistent in children of mothers with type 1 diabetes (P < 0.0001) and children of nondiabetic mothers (P = 0.008). CONCLUSIONS The type 2 diabetes susceptibility alleles at HHEX-IDE and CDKAL1 loci are associated with low BMI at age 8 years in children who were born large for gestational age.
- 11 May 2010
- Published by American Diabetes Association in Diabetes
- Vol. 59 (8) , 2063-2067
Open AccessBMI at Age 8 Years Is Influenced by the Type 2 Diabetes Susceptibility Genes HHEX-IDE and CDKAL1
OBJECTIVE To determine whether HHEX-IDE and CDKAL1 genes, which are associated with birth weight and susceptibility to type 2 diabetes, continue to influence growth during childhood. RESEARCH DESIGN AND METHODS BMI, weight, and height at age 8 years expressed as age- and sex-corrected standard deviation scores (SDS) against national reference data and single-nucleotide polymorphism genotyping of HHEX-IDE and CDKAL1 loci were analyzed in 646 prospectively followed children in the German BABYDIAB cohort. All children were singleton full-term births; 386 had mothers with type 1 diabetes, and 260 had fathers with type 1 diabetes and a nondiabetic mother. RESULTS Type 2 diabetes risk alleles at the HHEX-IDE locus were associated with reduced BMI-SDS at age 8 years (0.17 SDS per allele; P = 0.004). After stratification for birth weight, both HHEX-IDE and CDKAL1 risk alleles were associated with reduced BMI-SDS (0.45 SDS, P = 0.0002; 0.52 SDS, P = 0.0001) and weight-SDS (0.22 SDS, P = 0.04; 0.56 SDS, P = 0.0002) in children born large for gestational age (>90th percentile) but not children born small or appropriate for gestational age. Within children born large for gestational age, BMI and weight decreased with each additional type 2 diabetes risk allele (∼ −2 kg per allele; >8 kg overall). Findings were consistent in children of mothers with type 1 diabetes (P < 0.0001) and children of nondiabetic mothers (P = 0.008). CONCLUSIONS The type 2 diabetes susceptibility alleles at HHEX-IDE and CDKAL1 loci are associated with low BMI at age 8 years in children who were born large for gestational age.